Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 11.7 0.00% 0.00
SGMO closed unchanged on Thursday, April 18, 2019, on 74 percent of normal volume.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical SGMO trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -2.42%

Older signals for SGMO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Biotechnology Life Sciences Emerging Technologies Molecular Biology Glioblastoma Huntington's Disease Hemoglobinopathies Hemophilia A Hoffmann La Roche Lysosomal Storage Disorders
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.25
52 Week Low 6.26
Average Volume 2,791,944
200-Day Moving Average 12.5843
50-Day Moving Average 10.0553
20-Day Moving Average 11.2133
10-Day Moving Average 12.197
Average True Range 0.6715
ADX 29.01
+DI 25.389
-DI 17.9699
Chandelier Exit (Long, 3 ATRs ) 11.8955
Chandelier Exit (Short, 3 ATRs ) 10.7745
Upper Bollinger Band 14.1173
Lower Bollinger Band 8.3093
Percent B (%b) 0.58
BandWidth 51.795636
MACD Line 0.566
MACD Signal Line 0.6022
MACD Histogram -0.0362
Fundamentals Value
Market Cap 981.29 Million
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -14.44
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.29
Resistance 3 (R3) 12.26 12.04 12.19
Resistance 2 (R2) 12.04 11.89 12.05 12.15
Resistance 1 (R1) 11.87 11.80 11.96 11.90 12.12
Pivot Point 11.65 11.65 11.69 11.66 11.65
Support 1 (S1) 11.48 11.50 11.57 11.51 11.28
Support 2 (S2) 11.26 11.41 11.27 11.25
Support 3 (S3) 11.09 11.26 11.21
Support 4 (S4) 11.12